Stifel Nicolaus Has Lowered Expectations for Pyxis Oncology (NASDAQ:PYXS) Stock Price

Pyxis Oncology (NASDAQ:PYXS) had its target price reduced by Stifel Nicolaus from $9.00 to $8.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 459.44% from the company’s current price.

PYXS has been the subject of several other reports. Stephens increased their target price on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Royal Bank Of Canada lowered their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Pyxis Oncology has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Pyxis Oncology Stock Up 5.1%

Pyxis Oncology stock opened at $1.43 on Tuesday. The firm has a fifty day simple moving average of $1.51 and a two-hundred day simple moving average of $2.50. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The company has a market capitalization of $89.85 million, a PE ratio of -1.11 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter. As a group, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PYXS. Laurion Capital Management LP raised its position in Pyxis Oncology by 32.3% during the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after purchasing an additional 1,170,505 shares during the last quarter. Atle Fund Management AB bought a new stake in shares of Pyxis Oncology in the 4th quarter worth approximately $710,000. Bank of America Corp DE increased its stake in shares of Pyxis Oncology by 2,690.9% during the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after buying an additional 593,853 shares during the period. Longaeva Partners L.P. purchased a new position in shares of Pyxis Oncology during the third quarter valued at approximately $1,117,000. Finally, Jane Street Group LLC raised its holdings in shares of Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after acquiring an additional 482,310 shares in the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Key Pyxis Oncology News

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright raised its FY2029 EPS forecast for PYXS (from $0.21 to $0.27), reaffirmed a “Buy” rating and maintains a $7.00 price target — a strong institutional endorsement that can attract buyers and support the rally. HC Wainwright note via MarketBeat
• Neutral Sentiment: Stifel Nicolaus kept a “Buy” rating but lowered its price target from $9.00 to $8.00 — still a large upside versus current levels, but the downgrade in target is a mild headwind for further upside momentum. Benzinga
• Neutral Sentiment: Short-interest reports show effectively 0 shares short with inconsistent/NaN changes reported across data points — the published figures appear unreliable or immaterial, so short-covering is unlikely to be a driver in the near term. (Multiple short-interest entries aggregated.)
• Negative Sentiment: Director Rachel Humphrey executed multiple sales in April (notably 13,896 shares on Apr 21 at an average $1.03, plus earlier small sales on Apr 14 and Apr 17), reducing her holdings — insider selling can signal liquidity needs or waning conviction and may weigh on sentiment. SEC filing: Form 4

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.